← ANALYST RATINGS · TIPRANKS
Upstream Bio, Inc. (UPB): analyst forecast and price target
Analyst consensus
Strong Buy4 Buy1 Hold0 Sell
Ratings of 5 analysts in the last 3 months12-month forecast
Based on 5 price targets given in the last 3 months, the average target is $22.25, the highest $36.00, the lowest $9.00. The average is +706.2% from the last price of $2.76.
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $4.00 → $2.50−37.5% | Hold | −9.4% | Reiterated | 17.10.26on TipRanks 08:06 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $4.00 → $2.50−37.5% | Hold | −9.4% | Reiterated | 17.10.26on TipRanks 08:06 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $4.00 → $2.50−37.5% | Hold | −9.4% | Reiterated | 17.10.26on TipRanks 08:06 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $4.00 → $2.50−37.5% | Sell | −9.4% | Reiterated | 17.10.26on TipRanks 08:06 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $4.50 → $2.50−44.4% | Hold | −9.4% | Reiterated | 17.10.26on TipRanks 08:06 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $4.00 → $2.50−37.5% | Sell | −9.4% | Downgrade | 17.10.26on TipRanks 08:06 | — | |
| Matt Phipps★★★★★★★★★★#2652 · hits 48% · avg +4.8% | William Blair | — | Buy | — | Reiterated | 08.09.26on TipRanks 17:15 | −3.3%next day −2.9% · 5 days −9.5% | ↗ |
| Matthew Caufield★★★★★★★★★★#1718 · hits 42% · avg +10.1% | H.C. Wainwright | $36.00 | Buy | +1,204.3% | Reiterated | 02.09.26on TipRanks 06:15 | −1.5%next day −7.2% · 5 days −10.3% | ↗ |
| Kate Dellorusso★★★★★★★★★★#5737 · hits 57% · avg +7.2% | LifeSci Capital | $19.00 | Buy | +588.4% | Reiterated | 01.09.26on TipRanks 18:25 | −1.5%next day −7.2% · 5 days −10.3% | ↗ |
| Tessa Romero★★★★★★★★★★#805 · hits 57% · avg +21.7% | J.P. Morgan | $8.00 → $9.00+12.5% | Hold | +226.1% | Reiterated | 14.08.26on TipRanks 07:55 | +2.5%next day +1.5% · 5 days 0.0% | ↗ |
| Danielle Brill★★★★★★★★★★#566 · hits 56% · avg +16.1% | Truist Financial | $43.00 → $25.00−41.9% | Buy | +805.8% | Reiterated | 12.08.26on TipRanks Aug 11 15:00 | −4.4%next day −2.8% · 5 days −3.0% | ↗ |
| Yasmeen Rahimi★★★★★★★★★★#160 · hits 51% · avg +36.0% | Piper Sandler | $75.00 | Buy | +2,617.4% | Reiterated | 25.06.26on TipRanks 06:55 | 0.0%next day +6.9% · 5 days +16.7% | ↗ |
| Yaron Werber★★★★★★★★★★#117 · hits 59% · avg +28.0% | TD Cowen | — | Buy | — | Reiterated | 13.05.26on TipRanks 14:55 | +4.0%next day −6.9% · 5 days −10.0% | ↗ |
| Cory Kasimov★★★★★★★★★★#276 · hits 59% · avg +18.9% | Evercore ISI | $40.00 → $15.00−62.5% | Hold | +443.5% | Downgrade | 27.03.26on TipRanks 06:50 | −9.7%next day +1.6% · 5 days +8.2% | ↗ |
| No ratings for this filter. | ||||||||
The latest rating of each analyst in the last 12 months, as TipRanks lists them. Every rating kept, earlier ones included
Best analysts covering Upstream Bio, Inc.
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $22.25 at a price of $5.27 (+322.2%); now: $22.25 at $2.76 (+706.2%).
PriceAverage targetTop analysts’ target
Recommendation trend
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 10 | 10 | 7 | 6 | 6 | 6 |
| Buy | 8 | 3 | 3 | 1 | 3 | 3 |
| Hold | 1 | 1 | 1 | 2 | 2 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 05.11.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $-0.73 (from $-0.88 to $-0.52). Last quarter: $-0.73.
Sales
Next quarter’s sales estimate — $1M (from $0M to $1M). Last quarter: $1M.
Best top-analyst consensus in the sector · General
About Upstream Bio, Inc.
- CEO: E. Rand Sutherland
- Employees: 75
- 890 Winter Street, Waltham, MA, 02451, US
- upstreambio.com
Upstream Bio, Inc. is a biotechnology company in the clinical development stage, dedicated to innovating therapies for inflammatory conditions, particularly those affecting the severe respiratory system. Its pipeline notably features verekitug, a monoclonal antibody designed to selectively target and suppress the thymic stromal lymphopoietin receptor. Beyond this, the company is actively developing treatments for severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease. Established in 2021, Upstream Bio maintains its operational base in Waltham, Massachusetts.
Data from the stock’s TipRanks forecast page, read 20 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗